



Client Update

OCTOBER 2020 - INTERIM UPDATE

Test Name	Test Code	Effective Date
OnkoSight Advanced™ Next Generation Sequencing (NGS)	See Below	September 24

OnkoSight Advanced™ Next Generation Sequencing (NGS) panels are now available for New York patients for somatic (non-hereditary) tumor biopsy profiling.

- OnkoSight Advanced™ targeted NGS panels for solid and hematologic tumors include critical genomic biomarkers relevant to immunotherapy, Tumor Mutation Burden (TMB) and Tumor Only Microsatellite Instability (MSI)
- Genes included in each NGS panel are aligned with latest NCCN and WHO guideline recommendations
- Detected mutations are classified and reported in accordance with recently updated ASCO/AMP/CAP guidelines

Below are the new OnkoSight Advanced NGS Panels:

- TJ16-5 Solid Tumor Panel (50 genes, TMB, MSI)
- TH48-2 Prostate Cancer Panel (17 genes, TMB, MSI)
- TH49-9 Lung Cancer Panel (18 genes, TMB, MSI)
- TH50-8 Colorectal Cancer Panel (29 genes, TMB, MSI)
- TH53-2 GYN Tumor Panel (33 genes, TMB, MSI)
- TH57-3 CNS Panel (25 genes, TMB, MSI)
- TH58-1 GI Stromal Tumor Panel (9 genes, TMB, MSI)
- TH59-9 Melanoma Panel (25 genes, TMB, MSI)
- TH55-7 Chronic Lymphoid Neoplasms Panel (31 genes, TMB, MSI) (B-cell/T-cell non-Hodgkin Lymphomas/Leukemias, e.g. CLL/SLL, LPL/Waldenstrom Macroglobulinemia, T-LGLL, DLBCL, etc.)

Solid Tumor, Personalized Medicine, Hematopathology Hospital, and Hematopathology Office Test Requisition Forms have been updated to reflect the new test codes.

For full targeted gene lists and testing information, please visit www.genpath.com

New Test Information	
Test Codes/Gene Contents	<ul style="list-style-type: none"> • TJ16-5 – OnkoSight Advanced Solid Tumor Panel (50 genes, TMB and MSI) • TH48-2 – OnkoSight Advanced Prostate Cancer Panel (17 genes, TMB and MSI) • TH49-9 – OnkoSight Advanced Lung Cancer Panel (18 genes, TMB and MSI) • TH50-8 – OnkoSight Advanced Colorectal Cancer Panel (29 genes, TMB and MSI) • TH53-2 – OnkoSight Advanced GYN Tumor Panel (33 genes, TMB, MSI) • TH57-3- OnkoSight Advanced CNS Tumor Panel (26 genes, TMB and MSI) • TH58-1– OnkoSight Advanced Gastrointestinal Tumor Panel (9 genes, TMB and MSI) • TH59-9 – OnkoSight Advanced Melanoma Panel (26 genes, TMB and MSI) • TH55-7 – OnkoSight Advanced Chronic Lymphoid Neoplasms Panel (31 genes, TMB, MSI) (B-cell/T-cell non-Hodgkin Lymphomas/Leukemias, e.g. CLL/SLL, LPL/Waldenstrom Macroglobulinemia, T-LGLL, DLBCL etc.)
Primary Container	FFPE for solid tumor types; marrow aspirate or peripheral blood for chronic lymphoid neoplasm (Lavender (EDTA) or Green Top (NaH) tubes). Previously extracted DNA, or H&E plus 10-15 unstained slides, cytology smears are also acceptable.
Minimum Volume	Minimum 10% tumor cellularity, a minimum of ~40 ng DNA is required for technically adequate analysis
Turn Around Time	≤7-10 days
Transportation Temp	Ambient for FFPE, refrigerated for liquid samples
Stability	FFPE and DNA indefinite, Blood/Marrow: 30 days
Methodology	Genotyping by Next Generation Sequencing
Reference Range	See website for lists of targeted genes
CPT Code(s)**	81445/ 81450
Clinical Utility (If applicable)	Solid tumor or hematologic malignancy mutation profiling

NOTES:

To subscribe to receive client updates via email, please visit <http://bioreferencelabs.bioreference.com/go-green>

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.